Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORALStandard

MULPLETA

LUSUTROMBOPAG

Standard Dose
3MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: PRIORITY Marketing status: Prescription
Summary

Approval overview MULPLETA is listed in Drugs@FDA under application 210923 (NDA).

Review priority: PRIORITY Marketing status: Prescription Active ingredient LUSUTROMBOPAG Form and strength TABLET;ORAL - 3MG Sponsor VANCOCIN ITALIA Submission history Latest submission status date: 2018-07-31 00:00:00.

Structured Monograph

Clinical summary

Approval overview MULPLETA is listed in Drugs@FDA under application 210923 (NDA). Review priority: PRIORITY Marketing status: Prescription Active ingredient LUSUTROMBOPAG Form and strength TABLET;ORAL - 3MG Sponsor VANCOCIN ITALIA Submission history Latest submission status date: 2018-07-31 00:00:00. Submission type: ORIG.

Monitoring

  • • Marketing status: Prescription
  • • Review priority: PRIORITY

Interaction Notes

  • No interaction notes stored yet.
MULPLETA (LUSUTROMBOPAG) | Drug Monograph | MedicHelpline